IMP321 | No IMP321 | |
---|---|---|
N (%) | N (%) | |
Age | ||
Median | 49.5 | 56.8 |
Range | 35-73 | 48-70 |
Gender | ||
Male | 3 (50%) | 4 (66.6%) |
Female | 3 (50%) | 2 (33.3%) |
ECOG PS | ||
0 | 4 (66.6%) | 5 (83.3%) |
1 | 2 (33.3%) | 1 (16.6%) |
M sub-stage | ||
M1a | 3 (50%) | 1 (16.6%) |
M1b | 1 (16.6%) | 1 (16.6%) |
M1c | 2 (33.3%) | 4 (66.6%) |
Previous therapy for Stage IV | ||
Surgery | 1 (16.6%) | 2 (33.3%) |
CHT or RT | 2 (33.3%) | 1 (16.6%) |
Other | 2 (33.3%) | 0 (0%) |
Adjuvant immunotherapy | ||
Yes | 6 (100%) | 6 (100%) |
No | 0 (0%) | 0 (0%) |